bkkcommercialization
.pdf
keyboard_arrow_up
School
University of Texas *
*We aren’t endorsed by this school
Course
396
Subject
Economics
Date
Apr 3, 2024
Type
Pages
2
Uploaded by UltraFalconMaster1014
Develop your own perspective on whether you would advocate bringing BKK to market.
I would advocate for bringing BKK to market. There is huge medical need and benefits to
patients, as these drugs can be applied as anesthesia during surgeries for pain management
and as a treatment for depression and chronic pain—thereby alleviating stress and pain and
improving patient outcomes. Introducing such a novel package drug could also develop
advancements in advancements in medical science and pharmacology, contributing greatly to
ongoing research and development efforts and potentially leading to more effective and safer
treatments. Finally there is an economic incentive, as the anesthesia market is a crowning,
billion dollar industry, and the introduction of a novel form of a drug could be a huge financial
opportunity. In my personal experience working with health tech startups and briefly considering
a medical avenue for our technology, what I’ve mostly noticed is that there are a lot of unmet
needs in the health space, but regulation and the timeline for actually bringing products to
market can be long and arduous, and by the time it gets approved, market needs have
changed. However, based on key points in the case such as how BKK can be an alternative
aesthetic for people amidst the pressing opioid epidemic and be much more effective in pain
management (meeting a lot of unmet needs currently), I believe there is a lot of value, and that
the results of BKK can override the costs related to time and money for bringing this to market.
Which of the three options are best?
Below is a summary of the pros and cons of each option:
NDA
●
Confer additional patent protection and provide institutional support for marketing,
production, and distribution
●
Lots of interest from investors
●
Keep 35% of ownership
●
Highest sales and growth rate expectations
●
exposed HH to greater potential litigation costs
●
might lose control of his lifelong work
●
BKK combined bupivacaine with an NSAID, and most of the potential competing drugs
then in development leveraged a similar combination
●
patent challenges and lawsuits from the big pharmaceutical world would inhibit BKK’s
commercialization and overall success.
Compounding pharmacy partner
●
Delays in setting up production line
●
Compounding pharmacies limited in how they can market products
●
Annual growth rate and revenues expected to stagnant
Convenience kit
●
Longer shelf life
●
Large marketing network between physicians and sales representatives
●
No upfront costs
●
Most expensive
Based on these findings, I would suggest going with the NDA route. It has a lot of benefits, but
what is most appealing is the funding of the NDA process, which would speed up the time it
takes to go to market—this is especially crucial in a space where there is a lot of advancement
and competition. The compounding route seems to just have cons, and the convenience kit’s
appeal is the shelf life—however, these specifics drugs have a small duration of action, so they
would be used up quickly and the shelf life might not be much of an issue.
Would BKK be successful?
I think BKK would be successful—it’s a new kind of drug that addresses a high demand need in
anesthetize and also tackles other issues at the same time (eg opioid epidemic and
safety/efficiency). It seems like there is a lot of investor interest as well, and has the potential to
gain a lot of market share and generate revenue.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
Related Questions
What effects would joining a MCO have on your clinic regarding staffing, patient volume, and financial stability?What policies and procedures should be used by the MCOs to reduce costs for their clientele?
arrow_forward
You have been recruited as an expert in health economics to recommend
what is the best therapy for a group of patients. In the image below you will
find the decision tree showing the probabilities for different health states
and outcomes for patients undergoing two possible treatments, No drug
therapy and Drug therapy. Based on the expected cost, which therapy
would you recommend as the least expensive? Explain how you arrived at
your recommendation and show your calculations the space provided.
No drug theraphy ?
Drug theraphy
?
HEALTH STATES
PROBABILITIES
Remain in Good Health
0.5
Develop disease A
0.2
Develop disease B
0.2
Die
0.1
Remain in Good Health
0.53
Develop disease A
0.16
Develop disease B
0.22
Die
0.09
OUTCOMES
(Costs)
$0
$400
$300
$200
SO
$800
$500
$0
arrow_forward
Explain how the Orphan Drug Act would affect drug development. are there any tradeoffs from the act?
arrow_forward
In some countries, such as Canada and UK, direct-to-consumer (DTC) advertising for
pharmaceutical products is illegal or tightly controlled. Which of the following is NOT
a reason why DTC is tightly controlled?
DTC have the potential to drive up spending on drugs and exacerbate moral
hazard.
DTC makes patients aware of new remedies.
DTC can put a strain on doctor-patient relationship when patients demand some
drugs that are not necessary or not the best options.
Asymmetric information: consumers are not in a good position to determine if a
drug is what they need.
arrow_forward
Demand studies in health care have provided estimates of both income and price elasticity. Estimates of income elasticity are usually above +1.0. Estimates of price elasticity typically range between -0.1 and -.75 (with hospital services at the lower end and elective services at the upper end).
What information do these estimates convey?
What does the price elasticity of demand estimates imply for government policymakers, insurance companies, and medical providers' decisions?
What does the income elasticity of demand estimates imply for government policymakers, insurance companies, and medical providers' decisions?
arrow_forward
13
2013200
P0004
Suppose that a new drug (A) has been approved to treat a life-threatening disease. The demand for that drug is shown on the accompanying graph by
demand curve A Prior to approval of this drug, the only treatment for this condition was any one of several nonprescription, or over the counter, pain
relievers. The demand for one brand of the several nonprescription pain relievers is also shown on the graph as demand curve B.
Price
75
70
65
% 100 200 300 400 500
Quarsity
At a price of $15 (the price at which the two demand curves intersect), the price elasticity of demand for the new drug is
for the over-the-counter pain rellever
the price elasticity of demand
arrow_forward
Explain how the Orphan Drug Act would affect drug development. Can you think of any TRADEOFFS from the act?
arrow_forward
describe Diagnostic Research Design
arrow_forward
In some countries, such as Canada and UK, direct-to-consumer (DTC) advertising for pharmaceutical products is illegal or tightly controlled. Which of the following is NOT a reason why DTC is tightly controlled?
Question 7 options:
Asymmetric information: consumers are not in a good position to determine if a drug is what they need.
DTC makes patients aware of new remedies.
DTC can put a strain on doctor-patient relationship when patients demand some drugs that are not necessary or not the best options.
DTC have the potential to drive up spending on drugs and exacerbate moral hazard.
arrow_forward
Price controls decrease the innovation rate for drugs but make existing drugs
more affordable.
True
False
arrow_forward
The Orphan Drug Act of 1983 provides tax incentives, patent protection, and research subsidies to firms for drugs, vaccines, and diagnostic agents if they are intended to treat a disease that affects less than 200,000 citizens. Explain how the Orphan Drug Act would affect drug development. Can you think of any tradeoffs from the act?
arrow_forward
discuss some of the benefits and risks of new Health promoters basing their professional identities on established norms within this profession.
arrow_forward
Frustration over US pharmaceutical pricing has led researchers to develop frameworks for evaluation that can be used by any purchaser or patient making complex drug choices. One of the most prominent, the Institute for Clinical and Economic Review, uses clinical trial data and compares value -- per quality adjusted life year (QALY) -- under actual market pricing and other possible references prices for specific drugs.
Do you think $/QALY is an appropriate metric for evaluating the value of new drugs?
arrow_forward
Considering Healthcare price elasticity, would it be a good idea to implement a price increase on medical products?
arrow_forward
explain what implications physician-induced demand has for healthcare policy
arrow_forward
Consider two treatments. Treatment 1 saves one year of life at a cost of $10,000. Treatment 2 saves ten years of life at a cost of $1,000,000. Which treatment is more cost-effective? Why?
arrow_forward
What are some ways drug use has changed from early times to modern times ? What are some predictors of increased or decreased drug use in society ?
arrow_forward
How does its structure, conduct, and performance of the pharmaceutical industry impact patients?
arrow_forward
True or false and explain
State policies that mandated the release of physician report cards were greatly beneficial to consumers by allowing them to more efficiently search for high quality surgeons.
arrow_forward
Comment on the elasticity of demand for medicine
arrow_forward
What factors cause Physician Induced Demand, and how do you diagnose it?
arrow_forward
How can healthcare systems address the inelastic demand for emergency care to prevent unchecked and exorbitant pricing for patients?
arrow_forward
what is the relationship between the financial well-being of the industry and availability of healthcare, in consideration of market and demand theories?
arrow_forward
SEE MORE QUESTIONS
Recommended textbooks for you
Related Questions
- What effects would joining a MCO have on your clinic regarding staffing, patient volume, and financial stability?What policies and procedures should be used by the MCOs to reduce costs for their clientele?arrow_forwardYou have been recruited as an expert in health economics to recommend what is the best therapy for a group of patients. In the image below you will find the decision tree showing the probabilities for different health states and outcomes for patients undergoing two possible treatments, No drug therapy and Drug therapy. Based on the expected cost, which therapy would you recommend as the least expensive? Explain how you arrived at your recommendation and show your calculations the space provided. No drug theraphy ? Drug theraphy ? HEALTH STATES PROBABILITIES Remain in Good Health 0.5 Develop disease A 0.2 Develop disease B 0.2 Die 0.1 Remain in Good Health 0.53 Develop disease A 0.16 Develop disease B 0.22 Die 0.09 OUTCOMES (Costs) $0 $400 $300 $200 SO $800 $500 $0arrow_forwardExplain how the Orphan Drug Act would affect drug development. are there any tradeoffs from the act?arrow_forward
- In some countries, such as Canada and UK, direct-to-consumer (DTC) advertising for pharmaceutical products is illegal or tightly controlled. Which of the following is NOT a reason why DTC is tightly controlled? DTC have the potential to drive up spending on drugs and exacerbate moral hazard. DTC makes patients aware of new remedies. DTC can put a strain on doctor-patient relationship when patients demand some drugs that are not necessary or not the best options. Asymmetric information: consumers are not in a good position to determine if a drug is what they need.arrow_forwardDemand studies in health care have provided estimates of both income and price elasticity. Estimates of income elasticity are usually above +1.0. Estimates of price elasticity typically range between -0.1 and -.75 (with hospital services at the lower end and elective services at the upper end). What information do these estimates convey? What does the price elasticity of demand estimates imply for government policymakers, insurance companies, and medical providers' decisions? What does the income elasticity of demand estimates imply for government policymakers, insurance companies, and medical providers' decisions?arrow_forward13 2013200 P0004 Suppose that a new drug (A) has been approved to treat a life-threatening disease. The demand for that drug is shown on the accompanying graph by demand curve A Prior to approval of this drug, the only treatment for this condition was any one of several nonprescription, or over the counter, pain relievers. The demand for one brand of the several nonprescription pain relievers is also shown on the graph as demand curve B. Price 75 70 65 % 100 200 300 400 500 Quarsity At a price of $15 (the price at which the two demand curves intersect), the price elasticity of demand for the new drug is for the over-the-counter pain rellever the price elasticity of demandarrow_forward
- Explain how the Orphan Drug Act would affect drug development. Can you think of any TRADEOFFS from the act?arrow_forwarddescribe Diagnostic Research Designarrow_forwardIn some countries, such as Canada and UK, direct-to-consumer (DTC) advertising for pharmaceutical products is illegal or tightly controlled. Which of the following is NOT a reason why DTC is tightly controlled? Question 7 options: Asymmetric information: consumers are not in a good position to determine if a drug is what they need. DTC makes patients aware of new remedies. DTC can put a strain on doctor-patient relationship when patients demand some drugs that are not necessary or not the best options. DTC have the potential to drive up spending on drugs and exacerbate moral hazard.arrow_forward
- Price controls decrease the innovation rate for drugs but make existing drugs more affordable. True Falsearrow_forwardThe Orphan Drug Act of 1983 provides tax incentives, patent protection, and research subsidies to firms for drugs, vaccines, and diagnostic agents if they are intended to treat a disease that affects less than 200,000 citizens. Explain how the Orphan Drug Act would affect drug development. Can you think of any tradeoffs from the act?arrow_forwarddiscuss some of the benefits and risks of new Health promoters basing their professional identities on established norms within this profession.arrow_forward
arrow_back_ios
SEE MORE QUESTIONS
arrow_forward_ios
Recommended textbooks for you